Log in

SVNS Solvonis Therapeutics Plc LSE · United Kingdom

Solvonis Therapeutics Plc (SVNS) news

Solvonis Therapeutics Plc is a public biotech or pharmaceutical company listed on LSE under the ticker SVNS, recorded under United Kingdom. The directory classifies it as CNS drug developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Latest Solvonis Therapeutics Plc news

We have not published a story on Solvonis Therapeutics Plc yet. When there is news, it will appear here.

Questions about Solvonis Therapeutics Plc

What is the ticker symbol of Solvonis Therapeutics Plc?

Solvonis Therapeutics Plc trades under the ticker SVNS on LSE.

Where is Solvonis Therapeutics Plc listed?

Solvonis Therapeutics Plc is listed on LSE.

Which country or territory is Solvonis Therapeutics Plc listed under?

Our directory records Solvonis Therapeutics Plc under United Kingdom.

What does Solvonis Therapeutics Plc do?

Our directory classifies Solvonis Therapeutics Plc as: CNS drug developer. This is a directory classification, not a description of the pipeline.

What is the ISIN of Solvonis Therapeutics Plc?

The ISIN recorded for Solvonis Therapeutics Plc is GB00BMD1Z199.

Does aibio.space cover Solvonis Therapeutics Plc?

aibio.space lists Solvonis Therapeutics Plc among 2,820 public biotech companies and publishes its news here as stories appear.

Which companies are similar to Solvonis Therapeutics Plc?

Companies in our directory listed in the same country and business area as Solvonis Therapeutics Plc: Immunocore Holdings, Aptamer Group Plc, Alterola Biotech, Bioventix Plc, ValiRx, Kiniksa Pharmaceuticals International.

Investor discussion: Solvonis Therapeutics Plc

Members talk about Solvonis Therapeutics Plc (SVNS). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open LSE:SVNS on TradingView.

Listing details

Solvonis Therapeutics Plc is a public biotech or pharmaceutical company listed on LSE under the ticker SVNS, recorded under United Kingdom. The directory classifies it as CNS drug developer. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Solvonis Therapeutics Plc
Ticker
SVNS
Listing
LSE
Country or territory
United Kingdom
Business scope
CNS drug developer
ISIN
GB00BMD1Z199
Last quote in directory
2026-10-22
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.